Die nagemaakte swartmark semiglutide, wat bemark word as soos Ozempic, is nie by SAHPRA geregisteer nie. Inteendeel SAHPRA waarsku teen dié swartmark-produk. Lees hier wat SAHPRA sê: https://www.sahpra.org.za/news-and-updates/sahpras-position-on-semaglutide-compounded-products/ Luister Woensdag 11:30 na Gesondheid op RSG oor hierdie probleem. SAHPRA’s position on Semaglutide compounded products Pretoria, 13 December 2023 – The South African Health Products Regulatory Authority (SAHPRA) recently released a media statement on the falsified Ozempic products currently being sold on the market and online, specifically unauthorised Ozempic/semaglutide-containing products. SAHPRA has registered one product which contains semaglutide called Ozempic. There are two (2) registered presentations of the pre-filled injectable pen for Ozempic available in South Africa namely, Ozempic 0,25 mg and 0,5 mg/dose pen and Ozempic 1 mg/dose pen. Ozempic (each 1,0 ml solution contains Semaglutide 1,34 mg) is registered in South Africa for the treatment of adults with Type … Lees meer Swartmark ‘Ozempic’ kan gevaarlik wees en mag dalk selfs insulien bevat